Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

June 25, 2018

Why are There No Marches, Trending Hashtags or Walkouts?

Author(s):

Ryan Hamner

There can be definite struggles for childhood cancer survivors, even many years later.

There are marches, trending hashtags, walkouts and downright anger these days over just about everything. OK great, I get it. There's injustice. However, there's one group of people who are falling through the cracks, daily — people who really need help and who need a trending hashtag of their own. These people are childhood cancer survivors, and you can put me in the anger category on this one.

Many people like to think that cancer ends when treatment ends. In some cases, that's true, and that's great. In other cases, though, there are more battles to be fought, a lot more.

As I've written about before, many studies have shown that childhood cancer survivors are at a higher risk of suffering from heart disease, stroke, depression and other health issues later on in life. There are also plenty of studies that show we are more inclined to have issues with employment.

Do you trust the hiring manager that asks, "Did you really have cancer four times," or the would-be boss who asks, "What are your medical bills like," during an interview? Look, I've had some great coworkers, bosses and employers in my day who really understood and cared. However, I'll tell you, that's not always the case.

An employment attorney once made it very clear to me that cancer can often be a black mark on your record and lower your chances of getting hired. I've been given tips on how to work around this, but it can still be a challenge when it comes to finding a job, unfortunately.

Look, I get it, hiring someone who has had cancer and the side effects of cancer treatment for 35 years might not seem like the best business decision, but what are those survivors supposed to do? Most would like to be able to work just like everyone else. My go-to Google search for "childhood cancer survivors and employment" gives me nothing too promising in the results. As a matter of fact, just the opposite. I see articles about job-lock, insurance issues and employment issues all together.

It's great to see people walk for survivors every year. It's great to see companies donate to charities that fight against cancer and its effects. But personally, I think it would be awesome to see programs in place to support childhood cancer survivors who run into cancer-related issues further down the road.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Evens.
Image of carly.
Image of kelly.
Image of doctor.
Image of Dr. Kelly
image of doctor D'Sa
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Related Content
Advertisement
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of blood.
June 7th 2025

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
June 3rd 2025

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

Linda Cohen
I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.
The phase 1/2 STARLIGHT-1 trial evaluating EB103 has dosed the first patient  with advanced B-cell NHL: © stock.adobe.com.
May 30th 2025

First Patient Treated in Second Cohort of STARLIGHT-1 B-Cell NHL Trial

Ryan Scott
The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.
Related Content
Advertisement
The ADC zilovertamab vedotin plus Rituxan and chemo showed an ORR of 56.3% in relapsed/refractory DLBCL: © stock.adobe.com.
June 9th 2025

Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL

Silas Inman
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of blood.
June 7th 2025

KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety

Kristi Rosa
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
June 3rd 2025

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

Linda Cohen
I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.
The phase 1/2 STARLIGHT-1 trial evaluating EB103 has dosed the first patient  with advanced B-cell NHL: © stock.adobe.com.
May 30th 2025

First Patient Treated in Second Cohort of STARLIGHT-1 B-Cell NHL Trial

Ryan Scott
The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.